RT Journal Article
SR Electronic
T1 Impact of Duration of Cessation of Mass BCG Vaccination Programs on COVID-19 Mortality
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.20.20178889
DO 10.1101/2020.08.20.20178889
A1 Raham, Tareef Fadhil
YR 2020
UL http://medrxiv.org/content/early/2020/08/26/2020.08.20.20178889.abstract
AB Back ground BCG have heterogeneous immunity to certain pathogens other than Mycobacterium tuberculosis effect. At early times during COVID-19 pandemic heterogeneous immunity towards (SARS-CoV-2), was hypothesized and statistical correlation between of BCG vaccination practices and COVID-19 mortality variances among countries was statistically proved. These studies were criticized because of low evidence of such studies and possible confounding factors. For that reason, this study was designed to look for impact of duration of cessation of BCG programs on COVID-19 mortality looking for the hypotheses by different design and looking forward to support previous studies.Methods Total number of studied group is 14 countries which had stopped BCG vaccination programs.Through applying stem-leaf plot for exploring data screening behavior concerning COVID-19Mortality for obsolescence duration of cessation of mass BCG vaccination programs, as well as (nonlinear regression of compound model) for predicted shape behavior for that group.Results Slope value shows highly significant effectiveness of obsolescence of cessation of mass BCG vaccination programs on COVID-19 mortality at P-value<0.000. Obsolescence of duration of cessation of mass BCG vaccination programs has strong negative association with COVID-19 mortality in countries which stopped BCG vaccination programs.Conclusiaon The longer the cessation duration of BCG programs, the higher the COVID-19mortality is, and vice versa.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding ReceivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study did not involve human subjectsAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData used are publicly available